ArticleCommunications medicine2021
Next steps in the early detection of ovarian cancer.
Article in Communications medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Frequency of lymph node involvement in clinically early-stage low-grade serous ovarian cancer: a systematic review and meta-analysis.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2026Pooled it
- Can ovarian cancer screening work? A secondary analysis of the UK collaborative trial of ovarian cancer screening.British journal of cancer · 2026Article
- Novel Exploratory Transcriptomic Candidates as Biomarkers and Cancer Hallmark Fingerprints for Ovarian Endometroid and Clear Cell Carcinomas in Women.Antioxidants (Basel, Switzerland) · 2026Article
- Enhancing the positive predictive value of early-stage ovarian cancer detection using a two-step machine learning framework.Journal of translational medicine · 2026Article
- Gemcitabine activates the Hippo signaling pathway and suppresses tumor growth by stabilizing large tumor suppressor kinase 2 through the hypoxia-inducible factor 1-alpha/ubiquitin protein ligase E3 component N-recognin 5 axis.Journal of cell communication and signaling · 2026Article
- Clinical significance of circulating tumor DNA monitoring based on TP53 mutation in high-grade serous ovarian cancer patients.Translational cancer research · 2026Article
- Circulating Tumor DNA in Ovarian Cancer: Emerging Roles in Early Detection, Risk Stratification, and Disease Monitoring.Cancers · 2026Review
- Deep plasma proteomics identifies and validates an eight-protein biomarker panel that separate benign from malignant tumors in ovarian cancer.Communications medicine · 2025Article
- The Tie2 antagonist rebastinib reduces ovarian cancer growth in a syngeneic murine model.BMC cancer · 2025Article
- Novel diagnostics for improved treatment of gynecological cancer.Upsala journal of medical sciences · 2025Review
- Beyond tumor‑associated macrophages involved in spheroid formation and dissemination: Novel insights for ovarian cancer therapy (Review).International journal of oncology · 2024Review
- Large-scale proteomics reveals precise biomarkers for detection of ovarian cancer in symptomatic women.Scientific reports · 2024Article
- Normal Risk Ovarian Screening Study: 21-Year Update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Screening and prevention of ovarian cancer.The Medical journal of Australia · 2024Review
- Toward ovarian cancer screening with protein biomarkers using dried, self-sampled cervico-vaginal fluid.iScience · 2024Article
- Unveiling the Promise: A Comprehensive Review of Salpingectomy as a Vanguard for Ovarian Cancer Prevention.Cureus · 2024Review
- Top-Down Proteomics of Human Saliva, Analyzed with Logistic Regression and Machine Learning Methods, Reveal Molecular Signatures of Ovarian Cancer.International journal of molecular sciences · 2023Article
- Article
- The Potential of MicroRNAs as Clinical Biomarkers to Aid Ovarian Cancer Diagnosis and Treatment.Genes · 2022Review
- Development of a Multiprotein Classifier for the Detection of Early Stage Ovarian Cancer.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
A recent ovarian cancer screening trial found no reduction in mortality, despite increased detection of early stage disease. Here, we discuss these findings and examine next steps to develop more effective approaches for the early detection of ovarian cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.